175 related articles for article (PubMed ID: 11125847)
1. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
Chan WK; Delucchi AB
Life Sci; 2000 Nov; 67(25):3103-12. PubMed ID: 11125847
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine.
Chan WK; Nguyen LT; Miller VP; Harris RZ
Life Sci; 1998; 62(10):PL135-42. PubMed ID: 9496718
[TBL] [Abstract][Full Text] [Related]
3. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5.
Chang TK; Yeung RK
Can J Physiol Pharmacol; 2001 Mar; 79(3):220-6. PubMed ID: 11294598
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.
Lee CA; Kadwell SH; Kost TA; Serabjit-Singh CJ
Arch Biochem Biophys; 1995 May; 319(1):157-67. PubMed ID: 7771780
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
6. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4.
Regev-Shoshani G; Shoseyov O; Kerem Z
Biochem Biophys Res Commun; 2004 Oct; 323(2):668-73. PubMed ID: 15369802
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components.
Piver B; Berthou F; Dreano Y; Lucas D
Toxicol Lett; 2001 Dec; 125(1-3):83-91. PubMed ID: 11701226
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages.
Piver B; Berthou F; Dreano Y; Lucas D
Life Sci; 2003 Jul; 73(9):1199-213. PubMed ID: 12818727
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.
Oda Y; Kharasch ED
J Pharmacol Exp Ther; 2001 Sep; 298(3):1021-32. PubMed ID: 11504799
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.
Yu C; Shin YG; Kosmeder JW; Pezzuto JM; van Breemen RB
Rapid Commun Mass Spectrom; 2003; 17(4):307-13. PubMed ID: 12569440
[TBL] [Abstract][Full Text] [Related]
15. Inhibition selectivity of grapefruit juice components on human cytochromes P450.
Tassaneeyakul W; Guo LQ; Fukuda K; Ohta T; Yamazoe Y
Arch Biochem Biophys; 2000 Jun; 378(2):356-63. PubMed ID: 10860553
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
17. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition.
Usia T; Watabe T; Kadota S; Tezuka Y
Life Sci; 2005 Apr; 76(20):2381-91. PubMed ID: 15748631
[TBL] [Abstract][Full Text] [Related]
18. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
19. Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors.
Hyrsova L; Vanduchova A; Dusek J; Smutny T; Carazo A; Maresova V; Trejtnar F; Barta P; Anzenbacher P; Dvorak Z; Pavek P
Toxicol Lett; 2019 Jan; 300():81-91. PubMed ID: 30394306
[TBL] [Abstract][Full Text] [Related]
20. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.
Kanamitsu S; Ito K; Green CE; Tyson CA; Shimada N; Sugiyama Y
Pharm Res; 2000 Apr; 17(4):419-26. PubMed ID: 10870985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
